

REFERENCES

- Sikka, S. C. (2001). Relative impact of oxidative stress on male reproductive function. *Current Medicinal Chemistry*, 8(7), 851–862.
<https://doi.org/10.2174/0929867013373039>
- Itokawa, H., Kishi, E., Morita, H., Takeya, K., & Iitaka, Y. (1991). Eurylene, a new squalene-type triterpene from *Eurycoma longifolia*. *Tetrahedron Letters*, 32(15), 1803–1804.
- Low, B.-S., Das, P. K., & Chan, K.-L. (2013). Standardized quassinoid-rich *Eurycoma longifolia* extract improved spermatogenesis and fertility in male rats via the hypothalamic–pituitary–gonadal axis. *Journal of Ethnopharmacology*, 145(3), 706–714.
<https://doi.org/https://doi.org/10.1016/j.jep.2012.11.013>
- Kuo, P.-C., Shi, L.-S., Damu, A. G., Su, C.-R., Huang, C.-H., Ke, C.-H., Wu, J.-B., Lin, A.-J., Bastow, K. F., Lee, K.-H., & Wu, T.-S. (2003). Cytotoxic and Antimalarial β -Carboline Alkaloids from the Roots of *Eurycoma longifolia*. *Journal of Natural Products*, 66(10), 1324–1327.
<https://doi.org/10.1021/np030277n>
- Chan, K., O'Neill, M., Phillipson, J., & Warhurst, D. (1986). Plants as Sources of Antimalarial Drugs. Part 3 1 *Eurycoma longifolia*. *Planta Medica*, 52, 105–107. <https://doi.org/10.1055/s-2007-969091>

- Itokawa, H., Kishi, E., Morita, H., & Takeya, K. (1992). Cytotoxic Quassinoids and Tirucallane-Type Triterpenes from the Woods of *Eurycoma longifolia*. *CHEMICAL & PHARMACEUTICAL BULLETIN*, 40, 1053–1055.
<https://doi.org/10.1248/cpb.40.1053>
- Morita, H., Kishi, E., Takeya, K., Itokawa, H., & Iitaka, Y. (1993). Highly oxygenated quassinoids from *Eurycoma longifolia*. *Phytochemistry*, 33(3), 691–696. [https://doi.org/https://doi.org/10.1016/0031-9422\(93\)85475-7](https://doi.org/https://doi.org/10.1016/0031-9422(93)85475-7)
- Kardono, L. B. S., Angerhofer, C. K., Tsauri, S., Padmawinata, K., Pezzuto, J. M., & Kinghorn, A. D. (1991). Cytotoxic and antimalarial constituents of the roots of *Eurycoma longifolia*. *Journal of Natural Products*, 54(5), 1360–1367.
- Nordin, B. E. C., Prince, R. L., & Tucker, G. R. R. (2008). Bone density and fracture risk. *Medical Journal of Australia*, 189(1), 7–8.
<https://doi.org/10.5694/j.1326-5377.2008.tb01885.x>
- Morita, H., Kishi, E., Takeya, K., Itokawa, H., & Iitaka, Y. (1993). Highly oxygenated quassinoids from *Eurycoma longifolia*. *Phytochemistry*, 33(3), 691–696. [https://doi.org/https://doi.org/10.1016/0031-9422\(93\)85475-7](https://doi.org/https://doi.org/10.1016/0031-9422(93)85475-7)
- Ali, J. M., & Saad, J. M. (1993). Biochemical effect of *Eurycoma longifolia* jack on the sexual behavior, fertility, sex hormone, and glycolysis. *Department of Biochemistry, University of Malaysia: PhD Dissertation*.

- Tambi, M., Imran, M. K., & Henkel, R. R. (2012). Standardised water-soluble extract of Eurycoma longifolia, Tongkat ali, as testosterone booster for managing men with late-onset hypogonadism? *Andrologia*, 44, 226–230.
- Melton, L. J., Chrischilles, E. A., Cooper, C., Lane, A. W., & Riggs, B. L. (1992). Perspective how many women have osteoporosis? *Journal of Bone and Mineral Research*, 7(9), 1005–1010.
<https://doi.org/10.1002/jbmr.5650070902>
- Farouk, A.-E., & Benafri, A. (2007). Antibacterial activity of Eurycoma longifolia Jack. A Malaysian medicinal plant. *Saudi Medical Journal*, 28(9), 1422–1424.
- Kamel, H. K. (2005). Male Osteoporosis. *Drugs & Aging*, 22(9), 741–748.
<https://doi.org/10.2165/00002512-200522090-00003>
- Shuid, A. N., Abu Bakar, M. F., Abdul Shukor, T. A., Muhammad, N., Mohamed, N., & Soelaiman, I. N. (2011). The anti-osteoporotic effect of Eurycoma Longifolia in aged orchidectomised rat model. *The Aging Male*, 14(3), 150–154. <https://doi.org/10.3109/13685538.2010.511327>
- Tambi, M. I. B. M., Imran, M. K., & Henkel, R. R. (2012). Standardised water-soluble extract of Eurycoma longifolia, Tongkat ali, as testosterone booster for managing men with late-onset hypogonadism? *Andrologia*, 44(SUPPL.1), 226–230. <https://doi.org/10.1111/j.1439-0272.2011.01168.x>

Lahrita, L., Kato, E., & Kawabata, J. (2015). Uncovering potential of Indonesian medicinal plants on glucose uptake enhancement and lipid suppression in 3T3-L1 adipocytes. *Journal of Ethnopharmacology*, 168, 229–236.
<https://doi.org/10.1016/j.jep.2015.03.082>

Anders, H.-J., & Fogo, A. B. (2014). Immunopathology of lupus nephritis. *Seminars in Immunopathology*, 36(4), 443–459.
<https://doi.org/10.1007/s00281-013-0413-5>

Mohd Effendy, N., Mohamed, N., Muhammad, N., Naina Mohamad, I., & Shuid, A. N. (2012). *Eurycoma longifolia*: Medicinal plant in the prevention and treatment of male osteoporosis due to androgen deficiency. *Evidence-Based Complementary and Alternative Medicine*, 2012.
<https://doi.org/10.1155/2012/125761>

Kanis, J. A., Johnell, O., Oden, A., Sembo, I., Redlund-Johnell, I., Dawson, A., De Laet, C., & Jonsson, B. (2000). Long-term risk of osteoporotic fracture in Malmö. *Osteoporosis International : A Journal Established as Result of Cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA*, 11(8), 669–674.
<https://doi.org/10.1007/s001980070064>

Bin Mohd Tambi, M. I., & Imran, M. K. (2010). *Eurycoma longifolia* Jack in managing idiopathic male infertility. *Asian Journal of Andrology*, 12(3), 376–380. <https://doi.org/10.1038/aja.2010.7>

- Cucak, H., Nielsen Fink, L., Højgaard Pedersen, M., & Rosendahl, A. (2015).
Enalapril treatment increases T cell number and promotes polarization
towards M1-like macrophages locally in diabetic nephropathy. *International
Immunopharmacology*, 25(1), 30–42.
<https://doi.org/10.1016/j.intimp.2015.01.003>
- Cucak, H., Grunnet, L. G., & Rosendahl, A. (2014). Accumulation of M1-like
macrophages in type 2 diabetic islets is followed by a systemic shift in
macrophage polarization. *Journal of Leukocyte Biology*, 95(1), 149–160.
<https://doi.org/10.1189/jlb.0213075>
- Dang, N., Choo, Y.-Y., Nguyen, T. D., Nam, N., Minh, C., & Lee, J.-H. (2015).
7-Methoxy-(9H- β -Carbolin-1-Il)-(E)-2-Propenoic Acid, a β -Carboline
Alkaloid from Eurycoma Longifolia, Exhibits Anti-Inflammatory Effects by
Activating the Nrf2/Heme Oxygenase-1 Pathway. *Journal of Cellular
Biochemistry*, 117. <https://doi.org/10.1002/jcb.25315>
- Ricardo, S. D., Goor, H. Van, & Eddy, A. A. (2008). Science in medicine
Macrophage diversity in renal injury and repair. *J Clin Invest.*, 118(11),
3522–3530. <https://doi.org/10.1172/JCI36150.3522>
- Nishida, M., Okumura, Y., Fujimoto, S.-I., Shiraishi, I., Itoi, T., & Hamaoka, K.
(2005). Adoptive transfer of macrophages ameliorates renal fibrosis in mice.
Biochemical and Biophysical Research Communications, 332(1), 11–16.
<https://doi.org/10.1016/j.bbrc.2005.04.083>

Talbott, S. M., Talbott, J. A., George, A., & Pugh, M. (2013). Effect of Tongkat Ali on stress hormones and psychological mood state in moderately stressed subjects. *Journal of the International Society of Sports Nutrition*, 10(1), 1.
<https://doi.org/10.1186/1550-2783-10-28>

Husen, R., Pihie, A. H. L., & Nallappan, M. (2004). Screening for antihyperglycaemic activity in several local herbs of Malaysia. *Journal of Ethnopharmacology*, 95(2–3), 205–208.
<https://doi.org/10.1016/j.jep.2004.07.004>

Bhat, R., & Karim, A. A. (2010). Tongkat Ali (*Eurycoma longifolia* Jack): a review on its ethnobotany and pharmacological importance. *Fitoterapia*, 81(7), 669–679. <https://doi.org/10.1016/j.fitote.2010.04.006>

Kuo, P. C., Damu, A. G., Lee, K. H., & Wu, T. S. (2004). Cytotoxic and antimalarial constituents from the roots of *Eurycoma longifolia*. *Bioorganic and Medicinal Chemistry*, 12(3), 537–544.
<https://doi.org/10.1016/j.bmc.2003.11.017>

Ma, L. J., Nakamura, S., Aldigier, J. C., Rossini, M., Yang, H., Liang, X., Nakamura, I., Marcantoni, C., & Fogo, A. B. (2005). Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1. *Journal of the American Society of Nephrology*, 16(4), 966–976. <https://doi.org/10.1681/ASN.2004060492>

Yang, H. C., Zuo, Y., & Fogo, A. B. (2010). Models of chronic kidney disease.

Drug Discovery Today: Disease Models, 7(1–2), 13–19.

<https://doi.org/10.1016/j.ddmod.2010.08.002>

Gnudi, L. (2015). A new chance to beat diabetic kidney disease: innate immunity

and MCP-1: a matter of good and bad macrophages? *Nephrology, Dialysis,*

Transplantation : Official Publication of the European Dialysis and

Transplant Association - European Renal Association, 30(4), 525–527.

<https://doi.org/10.1093/ndt/gfv053>

Shen, B., Liu, X., Fan, Y., & Qiu, J. (2014). Macrophages regulate renal fibrosis

through modulating TGF β superfamily signaling. *Inflammation*, 37(6),

2076–2084. <https://doi.org/10.1007/s10753-014-9941-y>

Ma, L.-J., & Fogo, A. B. (2003). Model of robust induction of glomerulosclerosis

in mice: importance of genetic background. *Kidney International*, 64(1),

350–355. <https://doi.org/10.1046/j.1523-1755.2003.00058.x>

Gnudi, L. (2015). A new chance to beat diabetic kidney disease: innate immunity

and MCP-1: a matter of good and bad macrophages? *Nephrology, Dialysis,*

Transplantation : Official Publication of the European Dialysis and

Transplant Association - European Renal Association, 30(4), 525–527.

<https://doi.org/10.1093/ndt/gfv053>

- Rosin, D. L., & Okusa, M. D. (2011). Dangers within: DAMP responses to damage and cell death in kidney disease. *Journal of the American Society of Nephrology*, 22(3), 416–425. <https://doi.org/10.1681/ASN.2010040430>
- Mulay, S. R., Linkermann, A., & Anders, H. J. (2016). Necroinflammation in Kidney Disease. *Journal of the American Society of Nephrology*, 27(1), 27–39. <https://doi.org/10.1681/ASN.2015040405>
- Anders, H. J., & Ryu, M. (2011). Renal microenvironments and macrophage phenotypes determine progression or resolution of renal inflammation and fibrosis. *Kidney International*, 80(9), 915–925. <https://doi.org/10.1038/ki.2011.217>
- Anders, H. J. (2010). Toll-like receptors and danger signaling in kidney injury. *Journal of the American Society of Nephrology*, 21(8), 1270–1274. <https://doi.org/10.1681/ASN.2010030233>
- Wang, Y., & Harris, D. C. H. (2011). Macrophages in renal disease. *Journal of the American Society of Nephrology*, 22(1), 21–27. <https://doi.org/10.1681/ASN.2010030269>
- Cao, Q., Harris, D. C. H., & Wang, Y. (2015). Macrophages in kidney injury, inflammation, and fibrosis. *Physiology*, 30(3), 183–194. <https://doi.org/10.1152/physiol.00046.2014>

- Wang, Y., Wang, Y. P., Zheng, G., Lee, V. W. S., Ouyang, L., Chang, D. H. H., Mahajan, D., Coombs, J., Wang, Y. M., Alexander, S. I., & Harris, D. C. H. (2007). Ex vivo programmed macrophages ameliorate experimental chronic inflammatory renal disease. *Kidney International*, 72(3), 290–299. <https://doi.org/10.1038/sj.ki.5002275>
- Wilson, H. M., Stewart, K. N., Brown, P. A. J., Anegon, I., Chettibi, S., Rees, A. J., & Kluth, D. C. (2002). Bone-marrow-derived macrophages genetically modified to produce IL-10 reduce injury in experimental glomerulonephritis. *Molecular Therapy*, 6(6), 710–717. <https://doi.org/10.1006/mthe.2002.0802>
- Gurtner, G. C., Werner, S., Barrandon, Y., & Longaker, M. T. (2008). Wound repair and regeneration. *Nature*, 453, 314+.
- Park, J. S., Svetkauskaite, D., He, Q., Kim, J. Y., Strassheim, D., Ishizaka, A., & Abraham, E. (2004). Involvement of Toll-like Receptors 2 and 4 in Cellular Activation by High Mobility Group Box 1 Protein. *Journal of Biological Chemistry*, 279(9), 7370–7377. <https://doi.org/10.1074/jbc.M306793200>
- Chen, R., Alvero, A. B., Silasi, D.-A., & Mor, G. (2007). Inflammation, cancer and chemoresistance: taking advantage of the toll-like receptor signaling pathway. *American Journal of Reproductive Immunology (New York, N.Y. : 1989)*, 57(2), 93–107. <https://doi.org/10.1111/j.1600-0897.2006.00441.x>
- Bowcutt, A. A. (2015). Discovering the e-relationship between babies and early e-literacy: A case study on the responses of babies aged 0-12 months to

traditional texts and electronic readers. *Dissertation Abstracts International*

Section A: Humanities and Social Sciences, 76(5-A(E)), No Pagination

Specified. <https://doi.org/10.1038/nri2215>.How

Chen, G. Y., & Nuñez, G. (2010). Sterile inflammation: Sensing and reacting to

damage. *Nature Reviews Immunology*, 10(12), 826–837.

<https://doi.org/10.1038/nri2873>

Cao, Q., Wang, Y., & Harris, D. C. H. (2013). Pathogenic and protective role of

macrophages in kidney disease. *American Journal of Physiology. Renal*

Physiology, 305(1), F3–F11. <https://doi.org/10.1152/ajprenal.00122.2013>

Jonathan Posner, James A. Russell, and B. S. P. (2008). 基因的改变NIH Public

Access. *Bone*, 23(1), 1–7. <https://doi.org/10.1038/jid.2014.371>

Engler, A. E., Ysasi, A. B., Pihl, R. M. F., Villacorta-Martin, C., Heston, H. M.,

Richardson, H. M. K., Moniz, N. R., Belkina, A., Mazzilli, S. A., & Rock, J.

R. (2020). Airway-Associated Macrophages in Homeostasis and Repair.

SSRN Electronic Journal, 1–25. <https://doi.org/10.2139/ssrn.3639612>

Novak, M. L., & Koh, T. J. (2013). Macrophage phenotypes during tissue repair.

Journal of Leukocyte Biology, 93(6), 875–881.

<https://doi.org/10.1189/jlb.1012512>

Sorokin, Y., Romero, R., Mele, L., Wapner, R. J., Iams, J. D., Dudley, D. J.,

Spong, C. Y., Peaceman, A. M., Leveno, K. J., Harper, M., Caritis, S. N.,

Miodovnik, M., Mercer, B. M., Thorp, J. M., O'Sullivan, M. J., Ramin, S. M., Carpenter, M. W., Rouse, D. J., & Sibai, B. (2010). Maternal serum interleukin-6, C-reactive protein, and matrix metalloproteinase-9 concentrations as risk factors for preterm birth <32 weeks and adverse neonatal outcomes. *American Journal of Perinatology*, 27(8), 631–640. <https://doi.org/10.1055/s-0030-1249366>

Holder, B. S., Tower, C. L., Jones, C. J. P., Aplin, J. D., & Abrahams, V. M. (2012). Heightened Pro-Inflammatory Effect of Preeclamptic Placental Microvesicles on Peripheral Blood Immune Cells in Humans. *Biology of Reproduction*, 86(4). <https://doi.org/10.1095/biolreprod.111.094631>

Gordon, S. (2007). The macrophage: Past, present and future. *European Journal of Immunology*, 37(SUPPL. 1). <https://doi.org/10.1002/eji.200737638>

Porta, C., Paglino, C., Imarisio, I., & Bonomi, L. (2007). Cytokine-based immunotherapy for advanced kidney cancer: past results and future perspectives in the era of molecularly targeted agents. *TheScientificWorldJournal*, 7, 837–849. <https://doi.org/10.1100/tsw.2007.154>

Mosser, D. M., & Edwards, J. P. (2009). Nihms84393. *Nat Rev Immunology*, 8(12), 958–969. <https://doi.org/10.1038/nri2448>. Exploring

Dale, D. C., Boxer, L., & Liles, W. C. (2008). The phagocytes: neutrophils and monocytes. *Blood*, 112(4), 935–945. <https://doi.org/10.1182/blood-2007-12-077917>

Kitamoto, K., Machida, Y., Uchida, J., Izumi, Y., Shiota, M., Nakao, T., Iwao, H., Yukimura, T., Nakatani, T., & Miura, K. (2009). Effects of liposome clodronate on renal leukocyte populations and renal fibrosis in murine obstructive nephropathy. *Journal of Pharmacological Sciences*, 111(3), 285–292. <https://doi.org/10.1254/jphs.09227fp>

Mahdi, A. A., Bano, F., Singh, R., Singh, R. K., Siddiqui, M. S., & Hasan, M. (1999). Seminal plasma superoxide dismutase and catalase activities in infertile men. *Medical Science Research*, 27(3), 201–203.

scholar. (n.d.).

Lee, S., Huen, S., Nishio, H., Nishio, S., Lee, H. K., Choi, B.-S., Ruhrberg, C., & Cantley, L. G. (2011). Distinct macrophage phenotypes contribute to kidney injury and repair. *Journal of the American Society of Nephrology : JASN*, 22(2), 317–326. <https://doi.org/10.1681/ASN.2009060615>

Weiss, M., Byrne, A. J., Blazek, K., Saliba, D. G., Pease, J. E., Perocheau, D., Feldmann, M., & Udalova, I. A. (2015). IRF5 controls both acute and chronic inflammation. *Proceedings of the National Academy of Sciences of the United States of America*, 112(35), 11001–11006. <https://doi.org/10.1073/pnas.1506254112>

Jo, S.-K., Sung, S.-A., Cho, W.-Y., Go, K.-J., & Kim, H.-K. (2006). Macrophages

contribute to the initiation of ischaemic acute renal failure in rats.

Nephrology, Dialysis, Transplantation : Official Publication of the

European Dialysis and Transplant Association - European Renal

Association, 21(5), 1231–1239. <https://doi.org/10.1093/ndt/gfk047>

Tada, H., Yasuda, F., Otani, K., Doteuchi, M., Ishihara, Y., & Shiro, M. (1991).

New antiulcer quassinoids from *Eurycoma longifolia*. *European Journal of*

Medicinal Chemistry, 26(3), 345–349.

ITOKAWA, H., KISHI, E., MORITA, H., & TAKEYA, K. (1992). Cytotoxic

quassinoids and tirucallane-type triterpenes from the woods of *Eurycoma*

longifolia. *Chemical and Pharmaceutical Bulletin*, 40(4), 1053–1055.

Rubinstein, L. V, Shoemaker, R. H., Paull, K. D., Simon, R. M., Tosini, S.,

Skehan, P., Scudiero, D. A., Monks, A., & Boyd, M. R. (1990). Comparison

of in vitro anticancer-drug-screening data generated with a tetrazolium assay

versus a protein assay against a diverse panel of human tumor cell lines.

Journal of the National Cancer Institute, 82(13), 1113–1118.

<https://doi.org/10.1093/jnci/82.13.1113>

Ito, J., Chang, F. R., Wang, H. K., Park, Y. K., Ikegaki, M., Kilgore, N., & Lee,

K. H. (2001). Anti-AIDS agents. 48. Anti-HIV activity of moronic acid

derivatives and the new melliferone-related triterpenoid isolated from

Brazilian propolis. *Journal of Natural Products*, 64(10), 1278–1281.

<https://doi.org/10.1021/np010211x>

Kuo, P.-C., Shi, L.-S., Damu, A. G., Su, C.-R., Huang, C.-H., Ke, C.-H., Wu, J.-

B., Lin, A.-J., Bastow, K. F., & Lee, K.-H. (2003). Cytotoxic and antimalarial β -carboline alkaloids from the roots of *Eurycoma longifolia*. *Journal of Natural Products*, 66(10), 1324–1327.

Kuo, P.-C., Shi, L.-S., Damu, A. G., Su, C.-R., Huang, C.-H., Ke, C.-H., Wu, J.-

B., Lin, A.-J., Bastow, K. F., & Lee, K.-H. (2003). Cytotoxic and antimalarial β -carboline alkaloids from the roots of *Eurycoma longifolia*. *Journal of Natural Products*, 66(10), 1324–1327.

Nikolic-Paterson, D. J., Wang, S., & Lan, H. Y. (2014). Macrophages promote renal fibrosis through direct and indirect mechanisms. *Kidney International Supplements*, 4(1), 34–38. <https://doi.org/10.1038/kisup.2014.7>

Manuscript, A. (2016). *Europe PMC Funders Group Dendritic cells and macrophages in the kidney : a spectrum of good and evil*. 10(November 2013), 625–643. <https://doi.org/10.1038/nrneph.2014.170>.Dendritic

Martinez, F. O., & Gordon, S. (2014). The M1 and M2 paradigm of macrophage activation: Time for reassessment. *F1000Prime Reports*, 6(March), 1–13. <https://doi.org/10.12703/P6-13>

Castoldi, A., De Souza, C. N., Saraiva Câmara, N. O., & Moraes-Vieira, P. M.

(2016). The macrophage switch in obesity development. *Frontiers in Immunology*, 6(JAN), 1–11. <https://doi.org/10.3389/fimmu.2015.00637>

Mosser, D. M., & Edwards, J. P. (2008). Exploring the full spectrum of macrophage activation. *Nature Reviews. Immunology*, 8(12), 958–969. <https://doi.org/10.1038/nri2448>

Lech, M., Gröbmayer, R., Ryu, M., Lorenz, G., Hartter, I., Mulay, S. R., Susanti, H. E., Kobayashi, K. S., Flavell, R. A., & Anders, H.-J. (2014). Macrophage phenotype controls long-term AKI outcomes--kidney regeneration versus atrophy. *Journal of the American Society of Nephrology : JASN*, 25(2), 292–304. <https://doi.org/10.1681/ASN.2013020152>

Zhang, M., Singh, A., Harris, R. C., Zhang, M., Yao, B., Yang, S., Jiang, L., Wang, S., & Fan, X. (2012). *CSF-1 signaling mediates recovery from acute kidney injury Find the latest version : CSF-1 signaling mediates recovery from acute kidney injury*. 122(12), 4519–4532. <https://doi.org/10.1172/JCI60363.stem>

Review, I. (2008). *Immune activation and inflammation in HIV-1 infection : October 2007*, 231–241. <https://doi.org/10.1002/path>

Mantovani, A., Sica, A., Sozzani, S., Allavena, P., Vecchi, A., & Locati, M.

(2004). The chemokine system in diverse forms of macrophage activation

and polarization. *Trends in Immunology*, 25(12), 677–686.

<https://doi.org/10.1016/j.it.2004.09.015>

Mosser, D. M. (2003). The many faces of macrophage activation. *Journal of Leukocyte Biology*, 73(2), 209–212. <https://doi.org/10.1189/jlb.0602325>

Kim, M.-G., Kim, S. C., Ko, Y. S., Lee, H. Y., Jo, S.-K., & Cho, W. (2015). The Role of M2 Macrophages in the Progression of Chronic Kidney Disease following Acute Kidney Injury. *PloS One*, 10(12), e0143961. <https://doi.org/10.1371/journal.pone.0143961>

Gratchev, A., Guillot, P., Hakiy, N., Politz, O., Orfanos, C. E., Schledzewski, K., & Goerdts, S. (2001). Alternatively activated macrophages differentially express fibronectin and its splice variants and the extracellular matrix protein beta1G-H3. *Scandinavian Journal of Immunology*, 53(4), 386–392. <https://doi.org/10.1046/j.1365-3083.2001.00885.x>

Mantovani, A., Sica, A., Sozzani, S., Allavena, P., Vecchi, A., & Locati, M. (2004). The chemokine system in diverse forms of macrophage activation and polarization. *Trends in Immunology*, 25(12), 677–686. <https://doi.org/10.1016/j.it.2004.09.015>

Wang, Y., Wang, Y. P., Zheng, G., Lee, V. W. S., Ouyang, L., Chang, D. H. H., Mahajan, D., Coombs, J., Wang, Y. M., Alexander, S. I., & Harris, D. C. H. (2007). Ex vivo programmed macrophages ameliorate experimental chronic

inflammatory renal disease. *Kidney International*, 72(3), 290–299.

<https://doi.org/10.1038/sj.ki.5002275>

Martinez, F. O., Sica, A., Mantovani, A., & Locati, M. (2008). Macrophage activation and polarization. *Frontiers in Bioscience : A Journal and Virtual Library*, 13, 453–461. <https://doi.org/10.2741/2692>

Remuzzi, G., Benigni, A., Remuzzi, A., Remuzzi, G., Benigni, A., & Remuzzi, A. (2006). Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes Find the latest version : Science in medicine Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. *The Journal of Clinical Investigation*, 116(2), 288–296. <https://doi.org/10.1172/JCI27699.288>

Ricardo, S. D., Goor, H. Van, & Eddy, A. A. (2008). Science in medicine Macrophage diversity in renal injury and repair. *J Clin Invest.*, 118(11). <https://doi.org/10.1172/JCI36150.3522>

Alagesan, S., & Griffin, M. D. (2014). Alternatively activated macrophages as therapeutic agents for kidney disease: In vivo stability is a key factor. *Kidney International*, 85(4), 730–733. <https://doi.org/10.1038/ki.2013.405>

Cao, Q., Wang, Y., & Harris, D. C. H. (2014). Macrophage heterogeneity, phenotypes, and roles in renal fibrosis. *Kidney International Supplements*, 4(1), 16–19. <https://doi.org/10.1038/kisup.2014.4>

- et al., C. (2016). 乳鼠心肌提取 HHS Public Access. *Physiology & Behavior*, 176(1), 139–148. <https://doi.org/10.1016/j.physbeh.2017.03.040>
- Flaquer, M., Franquesa, M., Vidal, A., Bolaños, N., Torras, J., Lloberas, N., Herrero-Fresneda, I., Grinyó, J. M., & Cruzado, J. M. (2012). Hepatocyte growth factor gene therapy enhances infiltration of macrophages and may induce kidney repair in db/db mice as a model of diabetes. *Diabetologia*, 55(7), 2059–2068. <https://doi.org/10.1007/s00125-012-2535-z>
- de Zeeuw, D., Bekker, P., Henkel, E., Hasslacher, C., Gouni-Berthold, I., Mehling, H., Potarca, A., Tesar, V., Heerspink, H. J. L., & Schall, T. J. (2015). The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial. *The Lancet. Diabetes & Endocrinology*, 3(9), 687–696. [https://doi.org/10.1016/S2213-8587\(15\)00261-2](https://doi.org/10.1016/S2213-8587(15)00261-2)
- Athimulam, A., Kumaresan, S., Foo, D., Sarmidi, M., & Aziz, R. (2006). Modelling and Optimization of Eurycoma longifolia Water Extract Production. *Food and Bioproducts Processing - FOOD BIOPROD PROCESS*, 84, 139–149. <https://doi.org/10.1205/fbp.06004>
- Jayne, D. R., Bruchfeld, A., Schaier, M., Ciechanowski, K., Harper, L., Jadoul, M., Segelmark, M., Selga, D., Szombati, I., Venning, M., Hugo, C., Van Daele, P. L., Viklicky, O., Potarca, A., Schall, T. J., & Bekker, P. (2014). OP0227 Oral C5a Receptor Antagonist CCX168 Phase 2 Clinical TRIAL in

Anca-Associated Renal Vasculitis: *Annals of the Rheumatic Diseases*,
73(Suppl 2), 148.1-148. <https://doi.org/10.1136/annrheumdis-2014-eular.3728>

Berger, S. P., & Daha, M. R. (2007). Complement in glomerular injury. *Seminars in Immunopathology*, 29(4), 375–384. <https://doi.org/10.1007/s00281-007-0090-3>

Chua, L. S., Amin, N. A. M., Neo, J. C. H., Lee, T. H., Lee, C. T., Sarmidi, M. R., & Aziz, R. A. (2011). LC-MS/MS-based metabolites of Eurycoma longifolia (Tongkat Ali) in Malaysia (Perak and Pahang). *Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences*, 879(32), 3909–3919. <https://doi.org/10.1016/j.jchromb.2011.11.002>

Fiaschetti, G., Grotzer, M. A., Shalaby, T., Castelletti, D., & Arcaro, A. (2011). Quassinoids: From traditional drugs to new cancer therapeutics. *Current Medicinal Chemistry*, 18(3), 316–328. <https://doi.org/10.2174/092986711794839205>

Morré, D. J., Grieco, P. A., & Morré, D. M. (1998). Mode of action of the anticancer quassinoids--inhibition of the plasma membrane NADH oxidase. *Life Sciences*, 63(7), 595–604. [https://doi.org/10.1016/s0024-3205\(98\)00310-5](https://doi.org/10.1016/s0024-3205(98)00310-5)

Hirsh, A. (2003). Male subfertility. *Bmj*, 327(7416), 669. <https://doi.org/10.1136/bmj.327.7416.669>

Ang, H. H., Cheang, H. S., & Yusof, A. P. (2000). Effects of *Eurycoma longifolia* Jack (Tongkat Ali) on the initiation of sexual performance of inexperienced castrated male rats. *Experimental Animals*, 49(1), 35–38.
<https://doi.org/10.1538/expanim.49.35>

Tran, T. V. A., Malainer, C., Schwaiger, S., Atanasov, A. G., Heiss, E. H., Dirsch, V. M., & Stuppner, H. (2014). NF- κ B inhibitors from *Eurycoma longifolia*. *Journal of Natural Products*, 77(3), 483–488.
<https://doi.org/10.1021/np400701k>

Miyake, K., Tezuka, Y., Awale, S., Li, F., & Kadota, S. (2009). Quassinoids from *Eurycoma longifolia*. *Journal of Natural Products*, 72(12), 2135–2140.
<https://doi.org/10.1021/np900486f>

Mahfudh, N., & Pihie, A. H. L. (2008). Eurycomanone induces apoptosis through the up-regulation of p53 in human cervical carcinoma cells. *Journal of Cancer Molecules*, 4(4), 109–115.

Chan, K., LEE, S. P., Sam, T. W., & Han, B. (1989). A quassinoid glycoside from the roots of *Eurycoma longifolia*. *Phytochemistry*, 28, 2857–2859.
[https://doi.org/10.1016/S0031-9422\(00\)98108-1](https://doi.org/10.1016/S0031-9422(00)98108-1)

White-Cooper, H., & Bausek, N. (2010). Evolution and spermatogenesis. *Philosophical Transactions of the Royal Society B: Biological Sciences*, 365(1546), 1465–1480. <https://doi.org/10.1098/rstb.2009.0323>

- Sharlip, I. D., Jarow, J. P., Belker, A. M., Lipshultz, L. I., Sigman, M., Thomas, A. J., Schlegel, P. N., Howards, S. S., Nehra, A., Damewood, M. D., Overstreet, J. W., & Sadovsky, R. (2002). Best practice policies for male infertility. *Fertility and Sterility*, 77(5), 873–882.
[https://doi.org/10.1016/s0015-0282\(02\)03105-9](https://doi.org/10.1016/s0015-0282(02)03105-9)
- Brugh, V. M. 3rd, & Lipshultz, L. I. (2004). Male factor infertility: evaluation and management. *The Medical Clinics of North America*, 88(2), 367–385.
[https://doi.org/10.1016/S0025-7125\(03\)00150-0](https://doi.org/10.1016/S0025-7125(03)00150-0)
- Park, S., Nhiem, N. X., Kiem, P. Van, Minh, C. Van, Tai, B. H., Kim, N., Yoo, H. H., Song, J.-H., Ko, H.-J., & Kim, S. H. (2014). Five new quassinoids and cytotoxic constituents from the roots of *Eurycoma longifolia*. *Bioorganic & Medicinal Chemistry Letters*, 24(16), 3835–3840.
<https://doi.org/https://doi.org/10.1016/j.bmcl.2014.06.058>
- Meng, D., Li, X., Han, L., Zhang, L., An, W., & Li, X. (2014). Four new quassinoids from the roots of *Eurycoma longifolia* Jack. *Fitoterapia*, 92, 105–110. <https://doi.org/https://doi.org/10.1016/j.fitote.2013.10.009>
- Darise, M., Kohda, H., Mizutani, K., & Tanaka, O. (1982). Eurycomanone and eurycomanol, quassinoids from the roots of *Eurycoma longifolia*. *Phytochemistry*, 21(8), 2091–2093.
[https://doi.org/https://doi.org/10.1016/0031-9422\(82\)83050-1](https://doi.org/https://doi.org/10.1016/0031-9422(82)83050-1)

- Chan, K. L., Choo, C. Y., Abdullah, N. R., & Ismail, Z. (2004). Antiplasmodial studies of Eurycoma longifolia Jack using the lactate dehydrogenase assay of Plasmodium falciparum. *Journal of Ethnopharmacology*, 92(2–3), 223–227. <https://doi.org/10.1016/j.jep.2004.02.025>
- Low, B. S., Teh, C. H., Yuen, K. H., & Chan, K. L. (2011). Physico-chemical Effects of the major quassinoids in a standardized Eurycoma longifolia extract (Fr 2) on the bioavailability and pharmacokinetic properties, and their implications for oral antimalarial activity. *Natural Product Communications*, 6(3), 337–341. <https://doi.org/10.1177/1934578x1100600307>
- Nadjm, B., & Behrens, R. H. (2012). Malaria: an update for physicians. *Infectious Disease Clinics of North America*, 26(2), 243–259. <https://doi.org/10.1016/j.idc.2012.03.010>
- Taylor, Steve M; Parobek, Christian M; Fairhurst, R. M. (2013). Malaria : a Systematic Review and Meta-Analysis. *National Institution of Health*, 12(6), 457–468. [https://doi.org/10.1016/S1473-3099\(12\)70055-5](https://doi.org/10.1016/S1473-3099(12)70055-5).Impact
- Low, B. S., Choi, S. B., Abdul Wahab, H., Kumar Das, P., & Chan, K. L. (2013). Eurycomanone, the major quassinoid in Eurycoma longifolia root extract increases spermatogenesis by inhibiting the activity of phosphodiesterase and aromatase in steroidogenesis. *Journal of Ethnopharmacology*, 149(1), 201–207. <https://doi.org/10.1016/j.jep.2013.06.023>

- Ismail, S. B., Wan Mohammad, W. M. Z., George, A., Nik Hussain, N. H.,
Musthapa Kamal, Z. M., & Liske, E. (2012). Randomized clinical trial on the
use of PHYSTA freeze-dried water extract of Eurycoma longifolia for the
improvement of quality of life and sexual well-being in men. *Evidence-
Based Complementary and Alternative Medicine*, 2012.
<https://doi.org/10.1155/2012/429268>
- Browne, O. T., & Bhandari, S. (2012). Interpreting and investigating proteinuria.
BMJ : British Medical Journal, 344, e2339.
<https://doi.org/10.1136/bmj.e2339>
- Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V.,
Abraham, J., Adair, T., Aggarwal, R., Ahn, S. Y., Alvarado, M., Anderson,
H. R., Anderson, L. M., Andrews, K. G., Atkinson, C., Baddour, L. M.,
Barker-Collo, S., Bartels, D. H., Bell, M. L., ... Memish, Z. A. (2012).
Global and regional mortality from 235 causes of death for 20 age groups in
1990 and 2010: a systematic analysis for the Global Burden of Disease
Study 2010. *Lancet (London, England)*, 380(9859), 2095–2128.
[https://doi.org/10.1016/S0140-6736\(12\)61728-0](https://doi.org/10.1016/S0140-6736(12)61728-0)
- Fraser, S. D. S., Roderick, P. J., McIntyre, N. J., Harris, S., McIntyre, C., Fluck,
R., & Taal, M. W. (2014). Assessment of proteinuria in patients with chronic
kidney disease stage 3: Albuminuria and non-albumin proteinuria. *PLoS
ONE*, 9(5). <https://doi.org/10.1371/journal.pone.0098261>

Johnson, D. W. (2011). Global proteinuria guidelines: Are we nearly there yet?

Clinical Biochemist Reviews, 32(2), 89–95.

Peralta, C. A., Katz, R., Sarnak, M. J., Ix, J., Fried, L. F., De Boer, I., Palmas, W.,

Siscovick, D., Levey, A. S., & Shlipak, M. G. (2011). Cystatin C identifies chronic kidney disease patients at higher risk for complications. *Journal of the American Society of Nephrology : JASN*, 22(1), 147–155.

<https://doi.org/10.1681/ASN.2010050483>

Thomas, R., Kanso, A., & Sedor, J. R. (2008). Chronic Kidney Disease and Its

Complications. *Primary Care - Clinics in Office Practice*, 35(2), 329–344.

<https://doi.org/10.1016/j.pop.2008.01.008>

Lamb, E. J., MacKenzie, F., & Stevens, P. E. (2009). How should proteinuria be detected and measured? *Annals of Clinical Biochemistry*, 46(3), 205–217.

<https://doi.org/10.1258/acb.2009.009007>

Coresh, J., Selvin, E., Stevens, L. A., Manzi, J., Kusek, J. W., Eggers, P., Van

Lente, F., & Levey, A. S. (2007). Prevalence of Chronic Kidney Disease in the United States. *JAMA*, 298(17), 2038–2047.

<https://doi.org/10.1001/jama.298.17.2038>

Coresh, J., Astor, B. C., Greene, T., Eknoyan, G., & Levey, A. S. (2003).

Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. *American Journal of Kidney Diseases : The Official Journal of the*

National Kidney Foundation, 41(1), 1–12.

<https://doi.org/10.1053/ajkd.2003.50007>

Couser, W. G., Remuzzi, G., Mendis, S., & Tonelli, M. (2011). The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. *Kidney International*, 80(12), 1258–1270.

<https://doi.org/10.1038/ki.2011.368>

Fujii, H., & Joki, N. (2017). Mineral metabolism and cardiovascular disease in CKD. *Clinical and Experimental Nephrology*, 21(Suppl 1), 53–63.

<https://doi.org/10.1007/s10157-016-1363-8>

Wright, J. T., Williamson, J. D., Whelton, P. K., Snyder, J. K., Sink, K. M., Rocco, M. V., Reboussin, D. M., Rahman, M., Oparil, S., Lewis, C. E., Kimmel, P. L., Johnson, K. C., Goff, D. C., Fine, L. J., Cutler, J. A., Cushman, W. C., Cheung, A. K., & Ambrosius, W. T. (2015). A randomized trial of intensive versus standard blood-pressure control. *New England Journal of Medicine*, 373(22), 2103–2116.

<https://doi.org/10.1056/NEJMoa1511939>

Bello, A. K., Alrukhaimi, M., Ashuntantang, G. E., Basnet, S., Rotter, R. C., Douthat, W. G., Kazancioglu, R., Köttgen, A., Nangaku, M., Powe, N. R., White, S. L., Wheeler, D. C., & Moe, O. (2017). Complications of chronic kidney disease: current state, knowledge gaps, and strategy for action.

Kidney International Supplements, 7(2), 122–129.

<https://doi.org/10.1016/j.kisu.2017.07.007>

Dreyer, G., Hull, S., Aitken, Z., Chesser, A., & Yaqoob, M. M. (2009). The effect of ethnicity on the prevalence of diabetes and associated chronic kidney disease. *QJM : Monthly Journal of the Association of Physicians*, 102(4), 261–269. <https://doi.org/10.1093/qjmed/hcn177>

Goldsmith, D., Ritz, E., & Covic, A. (2004). Vascular calcification: A stiff challenge for the nephrologist - Does preventing bone disease cause arterial disease? *Kidney International*, 66(4), 1315–1333. <https://doi.org/10.1111/j.1523-1755.2004.00895.x>

Hossain, M. P., Palmer, D., Goyder, E., & El Nahas, A. M. (2012). Social deprivation and prevalence of chronic kidney disease in the UK: workload implications for primary care. *QJM: An International Journal of Medicine*, 105(2), 167–175. <https://doi.org/10.1093/qjmed/hcr153>

Fraser, S. D. S., Aitken, G., Taal, M. W., Mindell, J. S., Moon, G., Day, J., O'Donoghue, D., & Roderick, P. J. (2015). Exploration of chronic kidney disease prevalence estimates using new measures of kidney function in the health survey for England. *PLoS ONE*, 10(2), 1–16. <https://doi.org/10.1371/journal.pone.0118676>

O'Callaghan, C. A., Shine, B., & Lasserson, D. S. (2011). Chronic kidney disease: A large-scale population-based study of the effects of introducing the CKD-

EPI formula for eGFR reporting. *BMJ Open*, 1(2), 1–10.

<https://doi.org/10.1136/bmjopen-2011-000308>

Hallan, S. I., Coresh, J., Astor, B. C., Åsberg, A., Powe, N. R., Romundstad, S.,
Hallan, H. A., Lydersen, S., & Holmen, J. (2006). International comparison
of the relationship of chronic kidney disease prevalence and ESRD risk.
Journal of the American Society of Nephrology, 17(8), 2275–2284.
<https://doi.org/10.1681/ASN.2005121273>

Al Nasser, M. S., Ali, A. S., Sattar, M. A. A., Abdulfattah, E. H., Khan, L. M., &
Al Alsheikh, K. A. (2016). Therapeutic Drug Monitoring of Tacrolimus in
Saudi Kidney Transplant Patients. *Journal of Nephrology & Therapeutics*,
06(05), 604–612. <https://doi.org/10.4172/2161-0959.1000264>

Tam, F. W. K., & Ong, A. C. M. (2020). Renal monocyte chemoattractant
protein-1: an emerging universal biomarker and therapeutic target for kidney
diseases? *Nephrology Dialysis Transplantation*, 35(2), 198–203.
<https://doi.org/10.1093/ndt/gfz082>

Riskesdas, K. (2018). Hasil Utama Riset Kesehata Dasar (RISKESDAS). *Journal
of Physics A: Mathematical and Theoretical*, 44(8), 1–200.
<https://doi.org/10.1088/1751-8113/44/8/085201>

Kasiske, B. (2014). KDIGO guideline on CKD. *Kidney International
Supplements*, 4(1), 1–66.

Gregg, L. P., Tio, M. C., Li, X., Adams-Huet, B., Lemos, J. A. D., & Hedayati, S.

S. (2018). Association of Monocyte Chemoattractant Protein-1 with Death and Atherosclerotic Events in Chronic Kidney Disease. *American Journal of Nephrology*, 47(6), 395–405. <https://doi.org/10.1159/000488806>

Guiteras, R., Flaquer, M., & Cruzado, J. M. (2016). Macrophage in chronic kidney disease. *Clinical Kidney Journal*, 9(6), 765–771. <https://doi.org/10.1093/ckj/sfw096>

Luyckx, V. A., Stanifer, J. W., & Tonelli, M. (2018). World Health Organization. Global Burden Of Kidney Disea. *Bulletin of the World Health Organization, March*, 414–422. <https://www.who.int/bulletin/volumes/96/6/17-206441-ab/es/>

Putri, A. Y., & Thaha, M. (2014). Role of oxidative stress on chronic kidney disease progression. *Acta Medica Indonesiana*, 46(3), 244–252.

O’Callaghan, C. A., Shine, B., & Lasserson, D. S. (2011). Chronic kidney disease: A large-scale population-based study of the effects of introducing the CKD-EPI formula for eGFR reporting. *BMJ Open*, 1(2), 1–10. <https://doi.org/10.1136/bmjopen-2011-000308>

Hajjouli, S., Chateauvieux, S., Teiten, M. H., Orlikova, B., Schumacher, M., Dicato, M., Choo, C. Y., & Diederich, M. (2014). Eurycomanone and eurycomanol from *Eurycoma longifolia* jack as regulators of signaling

pathways involved in proliferation, cell death and inflammation. *Molecules*, 19(9), 14649–14666. <https://doi.org/10.3390/molecules190914649>

Neusser, M. A., Lindenmeyer, M. T., Edenhofer, I., Gaiser, S., Kretzler, M., Regele, H., Segerer, S., & Cohen, C. D. (2011). Intrarenal production of B-cell survival factors in human lupus nephritis. *Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc*, 24(1), 98–107. <https://doi.org/10.1038/modpathol.2010.184>

Fraser, S., & Blakeman, T. (2016). Chronic kidney disease: identification and management in primary care. *Pragmatic and Observational Research, Volume 7*, 21–32. <https://doi.org/10.2147/por.s97310>

Hodgin, J. B., Nair, V., Zhang, H., Randolph, A., Harris, R. C., Nelson, R. G., Weil, E. J., Cavalcoli, J. D., Patel, J. M., Brosius, F. C., & Kretzler, M. (2013). Identification of cross-species shared transcriptional networks of diabetic nephropathy in human and mouse glomeruli. *Diabetes*, 62(1), 299–308. <https://doi.org/10.2337/db11-1667>

Marrero, M. B., Banes-Berceli, A. K., Stern, D. M., & Eaton, D. C. (2006). Role of the JAK/STAT signaling pathway in diabetic nephropathy. *American Journal of Physiology - Renal Physiology*, 290(4), 762–768. <https://doi.org/10.1152/ajprenal.00181.2005>

Berthier, C. C., Zhang, H., Schin, M., Henger, A., Nelson, R. G., Yee, B., Boucherot, A., Neusser, M. A., Cohen, C. D., Carter-Su, C., Argetsinger, L.

S., Rastaldi, M. P., Brosius, F. C., & Kretzler, M. (2009). Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy. *Diabetes*, 58(2), 469–477. <https://doi.org/10.2337/db08-1328>

Khan, Y. H., Sarrieff, A., Adnan, A. S., Khan, A. H., & Mallhi, T. H. (2016). Chronic kidney disease, fluid overload and diuretics: A complicated triangle. *PLoS ONE*, 11(7), 1–13. <https://doi.org/10.1371/journal.pone.0159335>

Kraut, J. A., & Madias, N. E. (2016). Metabolic Acidosis of CKD: An Update. *American Journal of Kidney Diseases : The Official Journal of the National Kidney Foundation*, 67(2), 307–317. <https://doi.org/10.1053/j.ajkd.2015.08.028>

Seok, S. J., Lee, E. S., Kim, G. T., Hyun, M., Lee, J. H., Chen, S., Choi, R., Kim, H. M., Lee, E. Y., & Chung, C. H. (2013). Blockade of CCL2/CCR2 signalling ameliorates diabetic nephropathy in db/db mice. *Nephrology Dialysis Transplantation*, 28(7), 1700–1710. <https://doi.org/10.1093/ndt/gfs555>

Morris, S. M., Gao, T., Cooper, T. K., Kepka-Lenhart, D., & Awad, A. S. (2011). Arginase-2 mediates diabetic renal injury. *Diabetes*, 60(11), 3015–3022. <https://doi.org/10.2337/db11-0901>

Urquhart-Secord, R., Craig, J. C., Hemmelgarn, B., Tam-Tham, H., Manns, B., Howell, M., Polkinghorne, K. R., Kerr, P. G., Harris, D. C., Thompson, S.,

Schick-Makaroff, K., Wheeler, D. C., van Biesen, W., Winkelmayr, W. C., Johnson, D. W., Howard, K., Evangelidis, N., & Tong, A. (2016). Patient and Caregiver Priorities for Outcomes in Hemodialysis: An International Nominal Group Technique Study. *American Journal of Kidney Diseases : The Official Journal of the National Kidney Foundation*, 68(3), 444–454. <https://doi.org/10.1053/j.ajkd.2016.02.037>

Combs, S. A., Teixeira, J. P., & Germain, M. J. (2015). Pruritus in Kidney Disease. *Seminars in Nephrology*, 35(4), 383–391. <https://doi.org/10.1016/j.semnephrol.2015.06.009>

Wiederkehr, M., & Krapf, R. (2001). Metabolic and endocrine effects of metabolic acidosis in humans. *Swiss Medical Weekly*, 131(9–10), 127–132.

Gaggl, M., Sliber, C., & Sunder-Plassmann, G. (2014). Effect of oral alkali supplementation on progression of chronic kidney disease. *Current Hypertension Reviews*, 10(2), 112–120. <https://doi.org/10.2174/1573402111666141231123314>

Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., Broedl, U. C., Inzucchi, S. E., Aizenberg, D., Ulla, M., Waitman, J., De Lored, L., Farías, J., Fideleff, H., Lagrutta, M., ... Hieke, S. (2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *New England*

Journal of Medicine, 373(22), 2117–2128.

<https://doi.org/10.1056/NEJMoA1504720>

Tuttle, K. R., Brosius, F. C., Adler, S. G., Kretzler, M., Mehta, R. L., Tumlin, J.

A., Tanaka, Y., Haneda, M., Liu, J., Silk, M. E., Cardillo, T. E., Duffin, K.

L., Haas, J. V., Macias, W. L., Nunes, F. P., & Janes, J. M. (2018).

JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: Results from
a Phase 2 randomized controlled clinical trial. *Nephrology Dialysis*

Transplantation, 33(11), 1950–1959. <https://doi.org/10.1093/ndt/gfx377>

Grandaliano, G., Gesualdo, L., Bartoli, F., Ranieri, E., Monno, R., Leggio, A.,

Paradies, G., Caldarulo, E., Infante, B., & Schena, F. P. (2000). MCP-1 and
EGF renal expression and urine excretion in human congenital obstructive
nephropathy. *Kidney International*, 58(1), 182–192.

<https://doi.org/10.1046/j.1523-1755.2000.00153.x>

Dimmock & Lawlor. (2017). 乳鼠心肌提取 HHS Public Access. *Physiology &*

Behavior, 176(12), 139–148. <https://doi.org/10.1016/j.physbeh.2017.03.040>

Deshmane, S. L., Kremlev, S., Amini, S., & Sawaya, B. E. (2009). Monocyte

chemoattractant protein-1 (MCP-1): an overview. *Journal of Interferon &*
Cytokine Research : The Official Journal of the International Society for
Interferon and Cytokine Research, 29(6), 313–326.

<https://doi.org/10.1089/jir.2008.0027>

- Mellado, M., Rodríguez-Frade, J. M., Aragay, A., del Real, G., Martín, A. M., Vila-Coro, A. J., Serrano, A., Mayor, F. J., & Martínez-A, C. (1998). The chemokine monocyte chemotactic protein 1 triggers Janus kinase 2 activation and tyrosine phosphorylation of the CCR2B receptor. *Journal of Immunology (Baltimore, Md. : 1950)*, 161(2), 805–813.
- Titan, S. M., Vieira, J. M. J., Dominguez, W. V, Moreira, S. R. S., Pereira, A. B., Barros, R. T., & Zatz, R. (2012). Urinary MCP-1 and RBP: independent predictors of renal outcome in macroalbuminuric diabetic nephropathy. *Journal of Diabetes and Its Complications*, 26(6), 546–553.
<https://doi.org/10.1016/j.jdiacomp.2012.06.006>
- Wada, T., Furuichi, K., Sakai, N., Iwata, Y., Yoshimoto, K., Shimizu, M., Takeda, S. I., Takasawa, K., Yoshimura, M., Kida, H., Kobayashi, K. I., Mukaida, N., Naito, T., Matsushima, K., & Yokoyama, H. (2000). Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. *Kidney International*, 58(4), 1492–1499.
<https://doi.org/10.1046/j.1523-1755.2000.00311.x>
- Eardley, K. S., Zehnder, D., Quinkler, M., Lepenies, J., Bates, R. L., Savage, C. O., Howie, A. J., Adu, D., & Cockwell, P. (2006). The relationship between albuminuria, MCP-1/CCL2, and interstitial macrophages in chronic kidney disease. *Kidney International*, 69(7), 1189–1197.
<https://doi.org/10.1038/sj.ki.5000212>

Heerspink, H. J. L., Kröpelin, T. F., Hoekman, J., & de Zeeuw, D. (2015). Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis. *Journal of the American Society of Nephrology : JASN*, 26(8), 2055–2064.
<https://doi.org/10.1681/ASN.2014070688>

Bakris, G. L., Agarwal, R., Chan, J. C., Cooper, M. E., Gansevoort, R. T., Haller, H., Remuzzi, G., Rossing, P., Schmieder, R. E., Nowack, C., Kolkhof, P., Joseph, A., Pieper, A., Kimmeskamp-Kirschbaum, N., & Ruilope, L. M. (2015). Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. *JAMA*, 314(9), 884–894.
<https://doi.org/10.1001/jama.2015.10081>

Barnett, A. H., Mithal, A., Manassie, J., Jones, R., Rattunde, H., Woerle, H. J., & Broedl, U. C. (2014). Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. *The Lancet. Diabetes & Endocrinology*, 2(5), 369–384. [https://doi.org/10.1016/S2213-8587\(13\)70208-0](https://doi.org/10.1016/S2213-8587(13)70208-0)

Vallon, V. (2014). Do tubular changes in the diabetic kidney affect the susceptibility to acute kidney injury? *Nephron - Clinical Practice*, 127(1–4), 133–138. <https://doi.org/10.1159/000363554>

- Gembardt, F., Bartaun, C., Jarzebska, N., Mayoux, E., Todorov, V. T.,
Hohenstein, B., & Hugo, C. (2014). The SGLT2 inhibitor empagliflozin
ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2
diabetic mice with and without hypertension. *American Journal of
Physiology - Renal Physiology*, 307(3), 317–325.
<https://doi.org/10.1152/ajprenal.00145.2014>
- Cravedi, P., Ruggenti, P., & Remuzzi, G. (2010). Which antihypertensive drugs
are the most nephroprotective and why? *Expert Opinion on
Pharmacotherapy*, 11, 2651–2663.
<https://doi.org/10.1517/14656566.2010.521742>
- Yavin, Y., Mansfield, T. A., Ptaszynska, A., Johnsson, K., Parikh, S., & Johnsson,
E. (2016). Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels
in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis. *Diabetes
Therapy : Research, Treatment and Education of Diabetes and
Related Disorders*, 7(1), 125–137. <https://doi.org/10.1007/s13300-015-0150-y>
- Cherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A.,
Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., & von Eynatten,
M. (2014). Renal hemodynamic effect of sodium-glucose cotransporter 2
inhibition in patients with type 1 diabetes mellitus. *Circulation*, 129(5),
587–597. <https://doi.org/10.1161/CIRCULATIONAHA.113.005081>

Holtkamp, F. A., De Zeeuw, D., Thomas, M. C., Cooper, M. E., De Graeff, P. A., Hillege, H. J. L., Parving, H. H., Brenner, B. M., Shahinfar, S., & Heerspink, H. J. L. (2011). An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. *Kidney International*, 80(3), 282–287.

<https://doi.org/10.1038/ki.2011.79>

Fried, L. F., Emanuele, N., Zhang, J. H., Brophy, M., Conner, T. A., Duckworth, W., Leehey, D. J., McCullough, P. A., O'Connor, T., Palevsky, P. M., Reilly, R. F., Seliger, S. L., Warren, S. R., Watnick, S., Peduzzi, P., & Guarino, P. (2013). Combined angiotensin inhibition for the treatment of diabetic nephropathy. *New England Journal of Medicine*, 369(20), 1892–1903.

<https://doi.org/10.1056/NEJMoa1303154>

Breyer, M. D., & Susztak, K. (2016). The next generation of therapeutics for chronic kidney disease. *Nature Reviews. Drug Discovery*, 15(8), 568–588.

<https://doi.org/10.1038/nrd.2016.67>

Fan, F. H., Zhang, X., Guo, H. Z., Xie, D., Ping, Y. C., Wei, R. Z., Jian, P. J., Liang, M., Guo, B. W., Zheng, R. L., & Ren, W. G. (2006). Efficacy and safety of benazepril for advanced chronic renal insufficiency. *New England Journal of Medicine*, 354(2), 131–140.

<https://doi.org/10.1056/NEJMoa053107>

- Bakris, G. L., Pitt, B., Weir, M. R., Freeman, M. W., Mayo, M. R., Garza, D., Stasiv, Y., Zawadzki, R., Berman, L., & Bushinsky, D. A. (2015). Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease the AMETHYST-DN randomized clinical trial. *JAMA - Journal of the American Medical Association*, 314(2), 151–161. <https://doi.org/10.1001/jama.2015.7446>
- Mehdi, U., & Toto, R. D. (2009). Anemia, diabetes, and chronic kidney disease. *Diabetes Care*, 32(7), 1320–1326. <https://doi.org/10.2337/dc08-0779>
- Schjoedt, K. J., Rossing, K., Juhl, T. R., Boomsma, F., Tarnow, L., Rossing, P., & Parving, H. H. (2006). Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. *Kidney International*, 70(3), 536–542. <https://doi.org/10.1038/sj.ki.5001580>
- Li, S. Y., Huang, P. H., Yang, A. H., Tarng, D. C., Yang, W. C., Lin, C. C., Chen, J. W., Schmid-Schönbein, G., & Lin, S. J. (2014). Matrix metalloproteinase-9 deficiency attenuates diabetic nephropathy by modulation of podocyte functions and dedifferentiation. *Kidney International*, 86(2), 358–369. <https://doi.org/10.1038/ki.2014.67>
- Sandborn, W. J., Ghosh, S., Panes, J., Vranic, I., Su, C., Rousell, S., & Niezychowski, W. (2012). Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. *New England Journal of Medicine*, 367(7), 616–624. <https://doi.org/10.1056/NEJMoa1112168>

- Woroniecka, K. I., Park, A. S. D., Mohtat, D., Thomas, D. B., Pullman, J. M., & Susztak, K. (2011). Transcriptome analysis of human diabetic kidney disease. *Diabetes*, 60(9), 2354–2369. <https://doi.org/10.2337/db10-1181>
- Stark, G. R., & Darnell, J. E. J. (2012). The JAK-STAT pathway at twenty. *Immunity*, 36(4), 503–514. <https://doi.org/10.1016/j.immuni.2012.03.013>
- Guan, L.-Z., Tong, Q., & Xu, J. (2015). Elevated serum levels of mannose-binding lectin and diabetic nephropathy in type 2 diabetes. *PloS One*, 10(3), e0119699. <https://doi.org/10.1371/journal.pone.0119699>
- Murray, P. J. (2007). The JAK-STAT Signaling Pathway: Input and Output Integration. *The Journal of Immunology*, 178(5), 2623–2629. <https://doi.org/10.4049/jimmunol.178.5.2623>
- Fleischmann, R., Kremer, J., Cush, J., Schulze-Koops, H., Connell, C. A., Bradley, J. D., Gruben, D., Wallenstein, G. V., Zvillich, S. H., & Kanik, K. S. (2012). Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. *New England Journal of Medicine*, 367(6), 495–507. <https://doi.org/10.1056/NEJMoa1109071>
- Keystone, E. C., Taylor, P. C., Drescher, E., Schlichting, D. E., Beattie, S. D., Berclaz, P.-Y., Lee, C. H., Fidelus-Gort, R. K., Luchi, M. E., Rooney, T. P., Macias, W. L., & Genovese, M. C. (2015). Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an

inadequate response to methotrexate. *Annals of the Rheumatic Diseases*,
74(2), 333–340. <https://doi.org/10.1136/annrheumdis-2014-206478>

Mathern, D. R., & Heeger, P. S. (2015). Molecules Great and Small: The
Complement System. *Clinical Journal of the American Society of
Nephrology : CJASN*, 10(9), 1636–1650.
<https://doi.org/10.2215/CJN.06230614>

Rother, R. P., Rollins, S. A., Mojcik, C. F., Brodsky, R. A., & Bell, L. (2007).
Discovery and development of the complement inhibitor eculizumab for the
treatment of paroxysmal nocturnal hemoglobinuria. *Nature Biotechnology*,
25(11), 1256–1264. <https://doi.org/10.1038/nbt1344>

Prasanna Kumar, K. M., Ghosh, S., Canovatchel, W., Garodia, N., & Rajashekar,
S. (2017). A review of clinical efficacy and safety of canagliflozin 300 mg in
the management of patients with type 2 diabetes mellitus. *Indian Journal of
Endocrinology and Metabolism*, 21(1), 196–209.
<https://doi.org/10.4103/2230-8210.196016>

Berger, S. P., & Daha, M. R. (2007). Complement in glomerular injury. *Seminars
in Immunopathology*, 29(4), 375–384. <https://doi.org/10.1007/s00281-007-0090-3>

Flyvbjerg, A. (2017). The role of the complement system in diabetic nephropathy.
Nature Reviews. Nephrology, 13(5), 311–318.
<https://doi.org/10.1038/nrneph.2017.31>

- Legendre, C. M., Licht, C., Muus, P., Greenbaum, L. A., Babu, S., Bedrosian C
Bingham, C., Cohen, D. J., Delmas, Y., Douglas, K., Eitner, F., Feldkamp,
T., Fouque, D., Furman, R. R., Gaber, O., Herthelius, M., Hourmant, M.,
Karpman, D., Lebranchu, Y., Mariat, C., ... Loirat, C. (2013). Terminal
complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.
New England Journal of Medicine, 368(23), 2169–2181.
<https://doi.org/10.1056/NEJMoa1208981>
- Guan, L.-Z., Tong, Q., & Xu, J. (2015). Elevated serum levels of mannose-
binding lectin and diabetic nephropathy in type 2 diabetes. *PloS One*, 10(3),
e0119699. <https://doi.org/10.1371/journal.pone.0119699>
- Breyer, M. D., & Susztak, K. (2016). Developing Treatments for Chronic Kidney
Disease in the 21st Century. *Seminars in Nephrology*, 36(6), 436–447.
<https://doi.org/10.1016/j.semnephrol.2016.08.001>
- Events, C., Patients, I. N., Chronic, W., & Disease, K. (2017). Death , Esrd and
Cardiovascular Events in Patients. *J Hypertens*, 34(2), 244–252.
<https://doi.org/10.1097/HJH.0000000000000779>.VISIT-TO-VISIT
- Morton, D. L., Thompson, J. F., Cochran, A. J., Mozzillo, N., Nieweg, O. E.,
Roses, D. F., Hoekstra, H. J., Karakousis, C. P., Puleo, C. A., Coventry, B.
J., Smithers, B. M., Paul, E., Kraybill, W. G., Mckinnon, J. G., Elashoff, R.,
Faries, M. B., Zealand, N., & Trials, M. (2014). *New England Journal*. 599–
609. <https://doi.org/10.1056/NEJMoa1310460>

- Xie, X., Liu, Y., Perkovic, V., Li, X., Ninomiya, T., Hou, W., Zhao, N., Liu, L.,
Lv, J., Zhang, H., & Wang, H. (2016). Renin-Angiotensin System Inhibitors
and Kidney and Cardiovascular Outcomes in Patients with CKD: A Bayesian
Network Meta-analysis of Randomized Clinical Trials. *American Journal of
Kidney Diseases*, 67(5), 728–741. <https://doi.org/10.1053/j.ajkd.2015.10.011>
- Hu, M. C., Kuro-O, M., & Moe, O. W. (2013). Klotho and chronic kidney
disease. *Contributions to Nephrology*, 180, 47–63.
<https://doi.org/10.1159/000346778>
- Goldsmith, D. J. A., Covic, A., Fouque, D., Locatelli, F., Olgaard, K., Rodriguez,
M., Spasovski, G., Urena, P., Zoccali, C., London, G. M., & Vanholder, R.
(2010). Endorsement of the Kidney Disease Improving Global Outcomes
(KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-
MBD) Guidelines: a European Renal Best Practice (ERBP) commentary
statement. *Nephrology, Dialysis, Transplantation : Official Publication of the
European Dialysis and Transplant Association - European Renal
Association*, 25(12), 3823–3831. <https://doi.org/10.1093/ndt/gfq513>
- Ketteler, M., Elder, G. J., Evenepoel, P., Ix, J. H., Jamal, S. A., Lafage-Proust,
M.-H., Shroff, R., Thadhani, R. I., Tonelli, M. A., Kasiske, B. L., Wheeler,
D. C., & Leonard, M. B. (2015). Revisiting KDIGO clinical practice
guideline on chronic kidney disease-mineral and bone disorder: a
commentary from a Kidney Disease: Improving Global Outcomes

controversies conference. In *Kidney international* (Vol. 87, Issue 3, pp. 502–528). <https://doi.org/10.1038/ki.2014.425>

Panwar, B., & Gutiérrez, O. M. (2016). Disorders of Iron Metabolism and Anemia in Chronic Kidney Disease. *Seminars in Nephrology*, 36(4), 252–261. <https://doi.org/10.1016/j.semnephrol.2016.05.002>

Novak, M., Winkelman, J. W., & Unruh, M. (2015). Restless Legs Syndrome in Patients With Chronic Kidney Disease. *Seminars in Nephrology*, 35(4), 347–358. <https://doi.org/10.1016/j.semnephrol.2015.06.006>

Vyas, S., Chesarone-Cataldo, M., Todorova, T., Huang, Y.-H., & Chang, P. (2013). A systematic analysis of the PARP protein family identifies new functions critical for cell physiology. *Nature Communications*, 4(1), 2240. <https://doi.org/10.1038/ncomms3240>

O'Shea, J. J., & Plenge, R. (2012). JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. *Immunity*, 36(4), 542–550. <https://doi.org/10.1016/j.immuni.2012.03.014>

Structural and chemical aspects of resistance to the antibiotic, fosfomycin, conferred by F. from B. cereus. (2011). 基因的改变 NIH Public Access. *Bone*, 23(1), 1–7. <https://doi.org/10.1161/CIRCULATIONAHA.110.956839>

O'Shea, J. J., & Plenge, R. (2013). JAKs and STATs in Immunoregulation and

Immune-Mediated Disease. *Immunity*, 36(4), 542–550.

<https://doi.org/10.1016/j.immuni.2012.03.014>.JAKs

Benz, K., Hilgers, K. F., Daniel, C., & Amann, K. (2018). Vascular Calcification

in Chronic Kidney Disease: The Role of Inflammation. *International Journal of Nephrology*, 2018. <https://doi.org/10.1155/2018/4310379>

Baigent, C., Landray, M. J., Reith, C., Emberson, J., Wheeler, D. C., Tomson, C.,

Wanner, C., Krane, V., Cass, A., Craig, J., Neal, B., Jiang, L., Hooi, L. S.,

Levin, A., Agodoa, L., Gaziano, M., Kasiske, B., Walker, R., Massy, Z. A.,

... Investigators, S. (2011). The effects of lowering LDL cholesterol with

simvastatin plus ezetimibe in patients with chronic kidney disease (Study of

Heart and Renal Protection): a randomised placebo-controlled trial. *Lancet*

(London, England), 377(9784), 2181–2192. [https://doi.org/10.1016/S0140-](https://doi.org/10.1016/S0140-6736(11)60739-3)

6736(11)60739-3

Fox, C. S., Matsushita, K., Woodward, M., Bilo, H. J. G., Chalmers, J., Lambers

Heerspink, H. J., Lee, B. J., Perkins, R. M., Rossing, P., Sairenchi, T.,

Tonelli, M., Vassalotti, J. A., Yamagishi, K., Coresh, J., De Jong, P. E., Wen,

C. P., & Nelson, R. G. (2012). Associations of kidney disease measures with

mortality and end-stage renal disease in individuals with and without

diabetes: A meta-analysis. *The Lancet*, 380(9854), 1662–1673.

[https://doi.org/10.1016/S0140-6736\(12\)61350-6](https://doi.org/10.1016/S0140-6736(12)61350-6)

- Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C. Y. (2004).
Chronic kidney disease and the risks of death, cardiovascular events, and
hospitalization. *New England Journal of Medicine*, 351(13), 1296–1305.
<https://doi.org/10.1056/NEJMoa041031>
- Hommos, M. S., Zeng, C., Liu, Z., Troost, J., Rosenberg, A., Palmer, M., Kremers,
W. K., Cornell, L. D., Fervenza, F. C., Barisoni, L., Rule, A. D., Clinic, M.,
Hospital, J., Diseases, C., Mott, C. S., Arbor, A., & Clinic, M. (2019). *HHS*
Public Access. 93(5), 1175–1182.
<https://doi.org/10.1016/j.kint.2017.09.028>.Global
- Fogo, A. B. (2015). Causes and pathogenesis of focal segmental
glomerulosclerosis. *Nature Reviews Nephrology*, 11(2), 76–87.
<https://doi.org/10.1038/nrneph.2014.216>
- Matlow, A. G., & Berte, L. M. (2004). Sources of Error in Laboratory Medicine.
Laboratory Medicine, 35(6), 331–334.
<https://doi.org/10.1309/jq84jpu4x41qefel>
- Gava, A. L., Freitas, F. P. S., Balarini, C. M., Vasquez, E. C., & Meyrelles, S. S.
(2012). Effects of 5/6 nephrectomy on renal function and blood pressure in
mice. *International Journal of Physiology, Pathophysiology and*
Pharmacology, 4(3), 167–173.
- Ohashi, K., Iwatani, H., Kihara, S., Nakagawa, Y., Komura, N., Fujita, K., Maeda,
N., Nishida, M., Katsube, F., Shimomura, I., Ito, T., & Funahashi, T. (2007).

Exacerbation of albuminuria and renal fibrosis in subtotal renal ablation model of adiponectin-knockout mice. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 27(9), 1910–1917. <https://doi.org/10.1161/ATVBAHA.107.147645>

Di Micco, L., Quinn, R. R., Ronksley, P. E., Bellizzi, V., Lewin, A. M., Cianciaruso, B., & Ravani, P. (2013). Urine creatinine excretion and clinical outcomes in CKD. *Clinical Journal of the American Society of Nephrology : CJASN*, 8(11), 1877–1883. <https://doi.org/10.2215/CJN.01350213>

Trevisan, A., Chiara, F., Mongillo, M., Quintieri, L., & Cristofori, P. (2012). Sex-related differences in renal toxicodynamics in rodents. *Expert Opinion on Drug Metabolism & Toxicology*, 8, 1173–1188. <https://doi.org/10.1517/17425255.2012.698262>

Delanaye, P., Cavalier, E., & Pottel, H. (2017). Serum Creatinine: Not so Simple! *Nephron*, 136(4), 302–308. <https://doi.org/10.1159/000469669>

de Castro, B. B. A. bre., Colugnati, F. A. ntoni. B., Cenedeze, M. A. ntoni., Suassuna, P. G. iovann. de A., & Pinheiro, H. S. (2014). Standardization of renal function evaluation in Wistar rats (*Rattus norvegicus*) from the Federal University of Juiz de Fora's colony. *Jornal Brasileiro de Nefrologia : 'orgão Oficial de Sociedades Brasileira e Latino-Americana de Nefrologia*, 36(2), 139–149. <https://doi.org/10.5935/0101-2800.20140023>

Bindroo S, Quintanilla Rodriguez BS, Challa HJ. Renal Failure. [Updated 2020

Aug 13]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing;

2020Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK519012/>

Topaloğlu, R. (2005). Progression to renal failure. *The Turkish Journal of Pediatrics, 47 Suppl*, 3–8.

Chertow, G. M., Burdick, E., Honour, M., Bonventre, J. V, & Bates, D. W. (2005). Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. *Journal of the American Society of Nephrology : JASN*, 16(11), 3365–3370. <https://doi.org/10.1681/ASN.2004090740>